Global biopharmaceutical leader Celltrion proudly announced its recognition as a “Top 1%” company within the highly competitive biotechnology sector, following the rigorous Corporate Sustainability Assessment (CSA) conducted by S&P Global.
The S&P Global Corporate Sustainability Assessment (CSA) is a highly respected evaluation framework, meticulously assessing the environmental, social, and governance (ESG) performance of over 12,000 companies across the globe. Only the most sustainable enterprises—those ranking in the top 1 percent, 5 percent, and 10 percent within their respective industries—are featured in its prestigious annual Sustainability Yearbook.
Demonstrating remarkable progress, Celltrion significantly advanced from its “Top 5%” ranking last year to secure the elite “Top 1%” position this year. This achievement distinguishes Celltrion as the sole Korean company to reach this top tier in the biotechnology sector. Furthermore, the company was honored with the coveted “Industry Mover” award, a testament to its outstanding year-on-year improvement in overall ESG scores and its unwavering commitment to corporate sustainability.
Celltrion emphasized that fostering an ESG-driven health care environment is not merely a goal, but a cornerstone deeply integrated into its overarching corporate strategy and mission.
Addressing the environmental pillar, Celltrion is actively implementing robust strategies to manage greenhouse gas emissions. The company has set an ambitious and clear target of achieving carbon neutrality across its operations by 2045, reflecting its dedication to environmental stewardship and a sustainable future.
Within the social domain, Celltrion actively champions community engagement and global health initiatives. This includes supporting innovative domestic biotechnology startups through dynamic open innovation programs. Additionally, proceeds generated from its internal charity bazaar, the “Celeb Market,” are strategically channeled towards enhancing vital health care access in underserved developing countries, such as Madagascar, demonstrating its commitment to social impact.
Regarding robust corporate governance, Celltrion has proactively adopted a sophisticated lead independent director system, aligning with the highest global standards for transparency and accountability. This strong governance framework contributed to an impressive shareholder return rate of 103 percent in 2025, which stands as the highest within the industry and underscores the company’s commitment to investor confidence and ethical leadership.
A Celltrion official commented on these significant accolades, stating, “Our recognition as a ‘Top 1%’ company and an ‘Industry Mover’ by S&P Global clearly validates our robust ESG performance and underscores our continuous, dedicated efforts towards sustainable improvement across all facets of our operations.”
Celltrion reaffirmed its unwavering dedication to further strengthening its foundation for sustainable growth. The company is committed to continually contributing to global human health and welfare, aiming to create long-term value for all stakeholders through responsible and innovative practices.
stlee0329
